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Abstract
Background
There are limited data on region-specific drug susceptibility of tuberculosis (TB) in Uganda.
We performed resistance testing on specimens collected from treatment-naive patients with
pulmonary TB in Southwestern Uganda for first and second line anti-TB drugs. We sought
to provide data to guide regional recommendations for empiric TB therapy.
Methods
Archived isolates, obtained from patients at Mbarara Regional Referral Hospital from Febru-
ary 2009 to February 2013, were tested for resistance to isoniazid and rifampicin using the
MTBDRplus and Xpert MTB/RIF assays. A subset of randomly selected isolates was tested
for second line agents, including fluoroquinolones (FQs), aminoglycosides, cyclic peptides,
and ethambutol using the MTBDRsl assay. We performed confirmatory testing for FQ resis-
tance using repeated MTBDRsl, the Mycobacteria growth indicator tube (MGIT) assay, and
sequencing of the gyrA and gyrB genes.
Results
We tested isolates from 190 patients. The cohort had a median age of 33 years (IQR 26-
43), 69% (131/190) were male, and the HIV prevalence was 42% (80/190). No isolates
(0/190) were rifampicin-resistant and only 1/190 (0.5%) was isoniazid-resistant. Among 92
isolates tested for second-line drug resistance, 71 (77%) had interpretable results, of which
none were resistant to aminoglycosides, cyclic peptides or ethambutol. Although 7 (10%)
PLOSONE | DOI:10.1371/journal.pone.0118191 February 6, 2015 1 / 5
a11111
OPEN ACCESS
Citation: Orikiriza P, Tibenderana B, Siedner MJ,
Mueller Y, Byarugaba F, Moore CC, et al. (2015) Low
Resistance to First and Second Line Anti-
Tuberculosis Drugs among Treatment Naive
Pulmonary Tuberculosis Patients in Southwestern
Uganda. PLoS ONE 10(2): e0118191. doi:10.1371/
journal.pone.0118191
Academic Editor: Dipankar Chatterji, Indian Institute
of Science, INDIA
Received: November 24, 2014
Accepted: January 6, 2015
Published: February 6, 2015
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made
available under the Creative Commons CC0 public
domain dedication.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was made possible by Medical
Education for Equitable Services to All Ugandans a
Medical Education Partnership Initiative grant number
5R24TW008886 from the Office of Global AIDS
Coordinator and the U. S. Department of Health and
Human Services, Health Resources and Services
Administration and National Institutes of Health.
Funding for the study was also provided in part by the
Pfizer Initiative in International Health and the Center
initially tested as resistant to FQs by the MTBDRsl assay, they were confirmed as suscepti-
ble by repeat MTBDRsl testing as well as by MGIT and gyrase gene sequencing
Conclusion
We found no MDR-TB and no resistance to ethambutol, FQs, or injectable anti-TB drugs in
treatment naïve patients with pulmonary TB in Southwestern Uganda. Standard treatment
guidelines for susceptible TB should be adequate for most patients with TB in this popula-
tion. Where possible, molecular susceptibility testing methods should be routinely validated
by culture methods.
Background
Uganda has one of the highest rates of tuberculosis (TB) in the world, with an estimated annual
incidence of 200/100,000 people [1]. National rates of multi-drug resistant TB (MDR-TB) are
estimated at 1.4% among newly diagnosed and 12.1% among previously treated patients [2].
The Mbarara Regional Referral Hospital, in partnership with Ministry of Health, Uganda re-
cently initiated an MDR-TB treatment program. However, there are limited drug resistance
data from Southwestern Uganda to guide second or third line therapy regimens.
The primary objective of our study was to estimate the regional levels of TB drug resistance
and to guide recommendations for treatment of naive and MDR-TB infected patients in the
Southwestern region. Our a priori hypothesis was that there would be high rates of FQ resistance
due to the widespread local use of FQs for treatment of respiratory and enteric infections [3].
Methods
Study site
Strains were isolated from sputum specimens collected as part of Epicentre Mbarara Research
Centre diagnostic tuberculosis studies at the Mbarara Regional Referral Hospital. Participants
were eligible if they had clinical suspicion of pulmonary tuberculosis, defined as 2 weeks of
cough and weight loss or night sweats, during the period February 2009—February 2013. All
participants were newly diagnosed TB patients at the time of sputum collection.
Laboratory Methods
Archived isolates were thawed from -80°C storage, sub-cultured onto Lowenstein-Jensen medi-
um and incubated at 37°C. Cultures were monitored weekly until growth was observed and
then colonies were inoculated into 7H9 broth and heat killed at 95°C in a heating block for
30 minutes.
Manufacturer guidelines were followed to perform the MTBDRplus PCR assay for isoniazid
and rifampicin resistance (Hain Lifesciences, Nehren, Germany). This assay detects mutations
in the rpoB gene (for rifampicin resistance), the katG gene, and the promoter region of the
inhA gene (for isoniazid resistance). The same isolates were also tested using the Xpert MTB/
RIF assay (Cepheid Sunnyvale, USA) with a protocol modification to dilute the culture in a 1:1
ratio with saline before adding the sample (according to ITM recommendation). Additional
testing of 92 randomly selected samples for second-line drug testing was performed using the
MTBDRsl assay. This assay detects mutations in the gyrA gene, 16S RNA rrs, and embB genes,
which confer resistance to FQ, aminoglycosides/cyclic peptides, and ethambutol, respectively.
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To confirm resistance, isolates with a FQ mutation by the MTBDRsl assay were re-tested at
the Ugandan National Tuberculosis Reference Laboratory, using Mycobacteria Growth Indica-
tor Tube (MGIT) drug susceptibility testing for ofloxacin and kanamycin, using a threshold of
susceptibility of 2ug/mL and 2.5ug/mL, respectively. Isolates with discordant results between
MTBDRsl and MGIT were tested for the gyrA and gyrB genes of the quinolone resistance deter-
mining region (QRDR) at the Institute of Tropical Medicine in Antwerp, Belgium, where puri-
fied PCR products were sequenced with the same primers using the ABI’s Big Dye Terminator
Kit (Applied Biosystems, USA) according to the manufacturer’s instructions [4]. The following
mutations were considered as indicative of resistance: Thyr-80, Ala-90, Gly-88, Asp-94, Ala 90,
Ala-74, Ser-91 and Ser-95, for the gyrA gene and 429bp QRDR on gyrA/B for the gyrB gene
[4]. The proportion of drug resistance for each drug testing was estimated and a confidence in-
terval of 95% was calculated using STATA version 12 (Statacorp, College Station, Texas).
Ethical considerations
The isolates were obtained from patients enrolled in studies approved by Faculty Research and
Ethics committee and the Institutional Review Board at Mbarara University of Science and
Technology, and the Uganda National Council for Sciences and Technology. All patients
signed informed consent to participate in the studies and any further testing on the isolates.
Results
Study participants
Isolates from 190 untreated study participants with positive TB sputum cultures were tested.
Approximately half (93/190, 49%) were fromMbarara District and the remaining were from
22 neighboring districts in southwestern Uganda. The majority (131/190, 69%) were male, the
median age was 33 years (IQR 26–43), and 42% (79/190) of the participants were HIV-
infected.
Resistance to first and second line drugs
No isolates (0/190, 0%, 95%CI 0.0–1.9%) were rifampicin-resistant using MTBDRplus and
Xpert MTB/RIF, while one (0.5%, 95%CI 0.0–2.9%) was isoniazid-resistant using MTBDRplus.
In a subset of 92 isolates, 71 (77%) had valid MTBDRsl assay results. None had detectable resis-
tance to ethambutol or aminoglycosides/cyclic peptides, but 7 (9.8%, 95%CI 4.0–19.3%) were
resistant to FQ on initial testing. However, the PCR products of the seven discordant isolates
were sequenced and all had wild-type versions of FQ resistance genes. Both repeat MTBDRsl
testing and MGIT culture testing confirmed them to be susceptible to FQ.
Discussion
In a sample of 190 treatment-naïve patients with pulmonary TB in Southwestern Uganda, we
found no rifampicin and minimal isoniazid (<1%) resistance using molecular-based resistance
assays. In a sub-set of these specimens, no resistance to ethambutol or aminoglycosides was
identified. FQ resistance using a molecular technique was detected but culture-based and se-
quencing assays did not confirm these results suggesting minimal resistance to FQs in this re-
gion as well. Our finding of low drug resistance rates to first line TB therapeutics is consistent
with prior studies in Uganda. In a recent national drug survey, the MDR-TB prevalence was
1.4% among newly diagnosed patients [2]. In Southwestern Uganda, the prevalence was 1.6%
in a similar population [7]. Similar rates were found in Rwanda (4.3%) [8], Kenya (3.2%) [9],
and Tanzania (0.7%) [10]. These are the first reported data on first and second line drug
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susceptibility in Southwestern Uganda and support current MDR-TB treatment guidelines in
Uganda, which recommend 6 months of daily kanamycin, levofloxacin, ethionamide, cycloser-
ine and pyrazinamide followed by 18 months of daily levofloxacin, ethionamide, cycloserine
and pyrazinamide as per WHO guidelines [6].
Despite frequent use of FQ in Uganda for respiratory infections per Ministry of Health
guidelines [3], resistance among TB isolates appears to be rare. While we did detect resistance
to FQ in 10% of isolates initially tested using the MTBDRsl, these results were not confirmed
with either culture or sequencing based confirmatory methods. The laboratory was using this
assay for the first time and found it very sensitive and prone to contamination. This could have
contributed to the high false positive results.
Similarly, in a small sample of the Uganda national survey (n = 31), no FQ resistance
was identified among MDR-TB patients [2]. The poor specificity of the MTBDRsl assay for
FQ resistance has been reported previously. A study from the Democratic Republic of
Congo reported a false positive rate of 57% for FQ resistance using this test [5]. Thus these
results should promote caution in the use of the MTBDRsl assay for detection of FQs
resistance and suggest the confirmation of resistance by the use of culture method
where possible.
These results should be interpreted with the following limitations in mind. First, the study
was limited to treatment-naïve individuals, so it does not represent resistance profiles from pa-
tients with treatment failure. Second, we primarily pursued molecular methods to estimate
drug resistance. The sensitivity for drug resistance based on mutations in katG (INH), rpoB
(RIF) and MDR-TB has been estimated at90%,97%, and 99%, respectively [11]. Moreover,
there is emerging data illustrating the complexity of TB drug resistance testing through pleo-
morphic drug effects, non-genetic resistance pathways, and discordance between genetic resis-
tance and minimum inhibitory concentration thresholds [12]. Lastly, there was a high rate of
PCR failure during testing with the MTBDRsl assay (23%), which might have contributed to
under-estimation of resistance prevalence.
In conclusion, there was no evidence of first or second line drug resistance among
treatment-naïve TB patients at Mbarara Regional Referral Hospital in Southwestern Uganda.
These data support current national guidelines to include FQs, as empiric therapy for MDR-
TB in the region. Future studies should investigate resistance patterns among previously treat-
ed patients and treatment failures, as well as evaluation of culture-based methods to corrobo-
rate our findings. Furthermore, molecular resistant testing should be routinely confirmed with
culture based methods where possible.
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